DK3060213T3 - Farmaceutiske sammensætninger omfattende antibakterielle midler - Google Patents

Farmaceutiske sammensætninger omfattende antibakterielle midler Download PDF

Info

Publication number
DK3060213T3
DK3060213T3 DK14806074.2T DK14806074T DK3060213T3 DK 3060213 T3 DK3060213 T3 DK 3060213T3 DK 14806074 T DK14806074 T DK 14806074T DK 3060213 T3 DK3060213 T3 DK 3060213T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
antibacterial agents
antibacterial
agents
pharmaceutical
Prior art date
Application number
DK14806074.2T
Other languages
Danish (da)
English (en)
Inventor
Sachin Bhagwat
Mahesh Vithalbhai Patel
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Application granted granted Critical
Publication of DK3060213T3 publication Critical patent/DK3060213T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
DK14806074.2T 2013-10-22 2014-10-22 Farmaceutiske sammensætninger omfattende antibakterielle midler DK3060213T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2014/065522 WO2015059643A1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
IN3309MU2013 IN2013MU03309A (enExample) 2013-10-22 2014-10-22

Publications (1)

Publication Number Publication Date
DK3060213T3 true DK3060213T3 (da) 2022-01-03

Family

ID=52003012

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14806074.2T DK3060213T3 (da) 2013-10-22 2014-10-22 Farmaceutiske sammensætninger omfattende antibakterielle midler

Country Status (18)

Country Link
US (1) US9827235B2 (enExample)
EP (1) EP3060213B1 (enExample)
JP (2) JP2016538258A (enExample)
KR (1) KR102340010B1 (enExample)
CN (2) CN113577084A (enExample)
AU (1) AU2014338612C1 (enExample)
BR (1) BR112016008979B1 (enExample)
CA (1) CA2928364C (enExample)
DK (1) DK3060213T3 (enExample)
ES (1) ES2902456T3 (enExample)
HU (1) HUE057504T2 (enExample)
IN (1) IN2013MU03309A (enExample)
MX (1) MX375934B (enExample)
NZ (1) NZ719215A (enExample)
PL (1) PL3060213T3 (enExample)
PT (1) PT3060213T (enExample)
RU (1) RU2702361C2 (enExample)
WO (1) WO2015059643A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2983674A1 (en) * 2015-05-07 2016-11-10 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN109310682A (zh) * 2016-06-17 2019-02-05 沃克哈特有限公司 抗菌组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465428B1 (en) * 1999-08-27 2002-10-15 Aventis Pharma S.A. Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime
CA2591157C (en) * 2004-12-17 2012-06-12 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections
RU2366450C1 (ru) * 2008-08-04 2009-09-10 Валентина Васильевна Малиновская Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций
JP5808860B2 (ja) * 2011-07-26 2015-11-10 ウォックハート リミテッド スルバクタム及びベータ−ラクタマーゼインヒビターを含む医薬組成物
JP5666743B2 (ja) * 2011-08-27 2015-02-12 ウォックハート リミテッド 1,6−ジアザビシクロ[3,2,1]オクタン−7−オン誘導体および細菌感染の処置におけるそれらの使用
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
WO2013180197A1 (ja) * 2012-05-30 2013-12-05 Meiji Seikaファルマ株式会社 新規β-ラクタマーゼ阻害剤とその製造法
CN104884092A (zh) * 2013-01-14 2015-09-02 沃克哈特有限公司 用于治疗细菌感染的组合物和方法

Also Published As

Publication number Publication date
MX2016005161A (es) 2016-10-05
HUE057504T2 (hu) 2022-05-28
PT3060213T (pt) 2021-12-24
BR112016008979A2 (enExample) 2017-08-01
PL3060213T3 (pl) 2022-02-14
KR20160072254A (ko) 2016-06-22
EP3060213A1 (en) 2016-08-31
JP2019116508A (ja) 2019-07-18
CN106102741A (zh) 2016-11-09
NZ719215A (en) 2020-04-24
EP3060213B1 (en) 2021-10-13
US20160303104A1 (en) 2016-10-20
US9827235B2 (en) 2017-11-28
MX375934B (es) 2025-03-07
CA2928364A1 (en) 2015-04-30
AU2014338612B2 (en) 2019-12-19
CN113577084A (zh) 2021-11-02
WO2015059643A1 (en) 2015-04-30
JP2016538258A (ja) 2016-12-08
JP6886996B2 (ja) 2021-06-16
RU2016115376A (ru) 2017-11-28
RU2702361C2 (ru) 2019-10-08
RU2016115376A3 (enExample) 2018-07-02
CA2928364C (en) 2021-11-23
ES2902456T3 (es) 2022-03-28
KR102340010B1 (ko) 2021-12-16
BR112016008979B1 (pt) 2023-04-25
AU2014338612C1 (en) 2020-09-24
IN2013MU03309A (enExample) 2015-07-17

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
EP3065716C0 (en) FORMULATIONS
PL3297605T3 (pl) Kompozycje farmaceutyczne do stosowania miejscowego
EP3004067A4 (en) FUNGICIDE COMPOSITIONS
EP2941128A4 (en) ANTIMICROBIAL COMPOSITIONS
EP2889350A4 (en) ADHESIVE COMPOSITION
DK3079666T3 (da) Farmaceutiske sammensætninger omfattende dimethylfumarat
DK2943549T3 (da) Synergistisk h2s-scavenger-sammensætning
BR112016010669A2 (pt) composição desinfetante
LT2968221T (lt) S-ketamino hidrochlorido farmacinė kompozicija
EP3043769C0 (en) Hypertonic antimicrobial therapeutic compositions
DK2994154T3 (da) Antimikrobielt peptid
DK3027750T3 (da) Biokatalytisk sammensætning
DK3051945T3 (da) Fungicidsammensætninger
DK3043778T3 (da) Farmaceutiske sammensætninger, der indeholder refametinib
DK2893929T3 (da) Antibiotisk ceftolozansammensætninger
CL2015003520A1 (es) Compuestos y composiciones anti microbianas
SMT201500214B (it) Nuova composizione farmaceutica per il trattamentodi infezioni fungine
EP2999689A4 (en) Cyanoacrylate compositions
DK2988733T3 (da) Farmaceutisk sammensætning indeholdende krystallin macitentan
DK2917212T3 (da) Antimikrobielle midler
EP3043644C0 (en) Antimicrobial composition
DK3003401T3 (da) Farmaceutisk præparat
EP2959776A4 (en) HERBICIDE COMPOSITION